Page last updated: 2024-09-05

sorafenib and rhamnetin

sorafenib has been researched along with rhamnetin in 2 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (rhamnetin)	Trials (rhamnetin)	Recent Studies (post-2010) (rhamnetin)
6,520	730	5,251	80	0	49

Protein Interaction Comparison

Protein	Taxonomy	rhamnetin (IC50)
Aldo-keto reductase family 1 member B1	Homo sapiens (human)	2.7
ELAV-like protein 3	Homo sapiens (human)	1.2
Inositol hexakisphosphate kinase 2	Homo sapiens (human)	1.8

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP	1
Cao, S; Feng, F; Jia, H; Jiang, Q; Li, B; Lu, J; Wei, L; Zhang, Y	1

Other Studies

2 other study(ies) available for sorafenib and rhamnetin

Article	Year
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents. Biochimica et biophysica acta, 2016, Volume: 1860, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays	2016
Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis. Food & function, 2021, Mar-21, Volume: 12, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Liver; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Pregnane X Receptor; Quercetin; Sorafenib	2021

Article

Year

Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.

Biochimica et biophysica acta, 2016, Volume: 1860, Issue:7

Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2016

Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis.

Food & function, 2021, Mar-21, Volume: 12, Issue:6

Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Liver; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Pregnane X Receptor; Quercetin; Sorafenib

2021